-
Je něco špatně v tomto záznamu ?
HPLC determination of arginases inhibitor N-(ω)-hydroxy-nor-L-arginine using core-shell particle column and LC-MS/MS identification of principal metabolite in rat plasma
M. Hroch, Z. Havlínová, M. Nobilis, J. Chládek,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- arginasa antagonisté a inhibitory MeSH
- arginin aplikace a dávkování analogy a deriváty krev farmakokinetika MeSH
- extrakce na pevné fázi metody MeSH
- krysa rodu rattus MeSH
- lineární modely MeSH
- pilotní projekty MeSH
- potkani Wistar MeSH
- reprodukovatelnost výsledků MeSH
- stabilita léku MeSH
- tandemová hmotnostní spektrometrie metody MeSH
- vysokoúčinná kapalinová chromatografie přístrojové vybavení metody MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
For the purpose of in vivo pharmacokinetic studies, an HPLC method was developed and validated for the quantification of N-(ω)-hydroxy-nor-L-arginine, L-arginine and N-(ω)-ethyl-L-arginine (internal standard) in rat plasma. Sample processing involved a solid-phase extraction on the Waters MCX cartridges and on-line pre-column derivatization of the analytes with o-phthaldialdehyde and 3-mercaptopropionic acid. Separation of the derivatives was carried out on a core-shell Kinetex C18 column in a gradient elution mode with a mobile phase consisting of methanol and water (pH=3.00 adjusted with formic acid). Fluorimetric detection with the excitation/emission wavelengths of 235/450 nm was used. The method was validated according to the FDA guidelines and applied to pilot pharmacokinetic experiments. An unknown metabolite was extracted from the plasma of Wistar rats after a single bolus of N-(ω)-hydroxy-nor-L-arginine (i.v. 10 mg kg(-1)). The metabolite was identified as nor-L-arginine using mass spectrometry. Validated method was successfully used for pilot pharmacokinetic experiment on rats.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12022361
- 003
- CZ-PrNML
- 005
- 20171219081113.0
- 007
- ta
- 008
- 120806s2012 ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jchromb.2011.11.022 $2 doi
- 035 __
- $a (PubMed)22142597
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Hroch, Miloš, $d 1976- $7 xx0076212 $u Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic. hrochm@lfhk.cuni.cz
- 245 10
- $a HPLC determination of arginases inhibitor N-(ω)-hydroxy-nor-L-arginine using core-shell particle column and LC-MS/MS identification of principal metabolite in rat plasma / $c M. Hroch, Z. Havlínová, M. Nobilis, J. Chládek,
- 520 9_
- $a For the purpose of in vivo pharmacokinetic studies, an HPLC method was developed and validated for the quantification of N-(ω)-hydroxy-nor-L-arginine, L-arginine and N-(ω)-ethyl-L-arginine (internal standard) in rat plasma. Sample processing involved a solid-phase extraction on the Waters MCX cartridges and on-line pre-column derivatization of the analytes with o-phthaldialdehyde and 3-mercaptopropionic acid. Separation of the derivatives was carried out on a core-shell Kinetex C18 column in a gradient elution mode with a mobile phase consisting of methanol and water (pH=3.00 adjusted with formic acid). Fluorimetric detection with the excitation/emission wavelengths of 235/450 nm was used. The method was validated according to the FDA guidelines and applied to pilot pharmacokinetic experiments. An unknown metabolite was extracted from the plasma of Wistar rats after a single bolus of N-(ω)-hydroxy-nor-L-arginine (i.v. 10 mg kg(-1)). The metabolite was identified as nor-L-arginine using mass spectrometry. Validated method was successfully used for pilot pharmacokinetic experiment on rats.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a arginasa $x antagonisté a inhibitory $7 D001119
- 650 _2
- $a arginin $x aplikace a dávkování $x analogy a deriváty $x krev $x farmakokinetika $7 D001120
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $x přístrojové vybavení $x metody $7 D002851
- 650 _2
- $a stabilita léku $7 D004355
- 650 _2
- $a lineární modely $7 D016014
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a extrakce na pevné fázi $x metody $7 D052616
- 650 _2
- $a tandemová hmotnostní spektrometrie $x metody $7 D053719
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Havlínová, Zuzana
- 700 1_
- $a Nobilis, Milan
- 700 1_
- $a Chládek, Jaroslav
- 773 0_
- $w MED00006642 $t Journal of chromatography. B, Analytical technologies in the biomedical and life sciences $x 1873-376X $g Roč. 880, č. 1 (2012), s. 90-99
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22142597 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120806 $b ABA008
- 991 __
- $a 20171219081309 $b ABA008
- 999 __
- $a ok $b bmc $g 944274 $s 779658
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 880 $c 1 $d 90-99 $i 1873-376X $m Journal of chromatography. B, Analytical technologies in the biomedical and life sciences $n J Chromatogr B Analyt Technol Biomed Life Sci $x MED00006642
- LZP __
- $a Pubmed-20120806/12/01